Brain training and new drug combo tested to fight memory loss in stroke risk patients

NCT ID NCT07605130

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study tests whether a tablet-based brain training program and/or a powerful cholesterol-lowering drug (PCSK9 inhibitor) can improve thinking and memory in 420 adults aged 55-80 with narrowed brain arteries. Participants will be split into four groups, combining or not combining the training with standard or intensive cholesterol treatment. The main goal is to see if these approaches boost cognitive scores after 24 weeks.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
Recaticimab (PCSK9 inhibitor) injection, plus statins and ezetimibe
What this could lead to
If successful, this could point toward a way to slow or improve cognitive decline in people with intracranial atherosclerosis.
What could go wrong
This is a Phase 4 trial with 420 participants, so results are not yet known. The cognitive training is intensive (30 min/day, 5 days/week), and the added drug may cause side effects like injection site reactions or muscle pain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COGNITIVE IMPAIRMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cognitive Dysfunction intracranial arteriosclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, 100730, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.